Evaluation of CHOP [cyclophosphamide, doxorubicin, vincristine, and prednisone] plus rituximab plus involved field radiotherapy for stages I, IE, and non-bulky stages II and IIE, CD20 positive, high-risk localized aggressive histologies of non-Hodgkin's lymphoma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 16 Jan 2017 Biomarkers information updated
- 12 Jan 2012 Actual patient number is 71 according to ClinicalTrials.gov.
- 12 Jan 2012 Planned end date 1 Jan 2017 added as reported by ClinicalTrials.gov.